Octapharma

This phase 3 study tests an intravenous C1 esterase inhibitor (C1-INH) in people with hereditary angioedema (HAE) to treat acute attacks and prevent attacks before medical procedures. About 124 participants, aged 2 and older, will receive either the drug or a placebo. The main go…

This study tests a drug called Atenativ in people with a rare inherited condition that raises their risk of dangerous blood clots. The goal is to see if Atenativ can prevent clots during surgery or childbirth. About 38 adults and some teens will take part. The drug is given as an…

This study tests a drug called Atenativ, made from human plasma, in 120 adults who are resistant to heparin during planned heart surgery. Heparin is a blood thinner used to prevent clots during surgery, but some patients don't respond well. The drug aims to restore heparin's effe…

This study tests whether a recombinant factor VIII product called Nuwiq can safely prevent bleeding during major surgery in people with severe hemophilia A who are already on emicizumab. About 28 male patients aged 12 and older will take part. The main goal is to see if the treat…

This study is testing a drug called Nuwiq, a lab-made clotting factor, to prevent excessive bleeding during major surgery in women and girls with hemophilia A. About 28 participants will receive Nuwiq around the time of their surgery. Researchers will check if the drug successful…

This study is observing how well three Factor VIII concentrates (Nuwiq, Octanate, Wilate) work in real-world settings for people with severe hemophilia A who have had little or no prior treatment. Researchers will track bleeding rates and side effects in about 200 participants of…